ENDRA Life Sciences reports expected Q1 2024 net loss of ~$2.8M, zero revenue; files for public offering

ENDRA Life Sciences Inc.

Expected Q1 2024 net loss of approx. $2.8M vs. $2.9M in Q1 2023; zero revenue in both quarters.
As of March 31, 2024, total assets ~$5.0M, cash ~$1.1M, working capital only ~$54k.
Filed Form S-1/A for public offering of common stock and warrants; terms not disclosed.
Preliminary results are unaudited and subject to final closing and audit adjustments.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENDRA Life Sciences Inc. reported the fiscal quarter ended March 31, 2024 results: net income We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2024.

Period: the fiscal quarter ended March 31, 2024
Net income: We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2024
Result: preliminary results

Exact text from the filing

On May 10, 2024, ENDRA Life Sciences Inc. (the “Company”) filed a Registration Statement (the “Prospectus”) on Form S-1/A (No. 333-278842) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), relating to a public offering (the “Offering”) of shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock. The Prospectus contains select preliminary unaudited estimated financial results for the fiscal quarter ended March 31, 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-005981

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.